Explore more about: Infectious Diseases

A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in the future.

A new study that could have immediate implications for COVID-19 testing in schools found that with age-appropriate instructions, school-aged children can successfully use a nasal swab to obtain their own COVID-19 test specimen.

Researchers funded by NIH's RADx Tech program have developed a fast, cost-effective method to detect the circulation of SARS-CoV-2 variants. The team adopted a customizable genotyping approach to identify known variants and subvariants—an approach that can augment current surveillance.

The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.

A new $13.3 million contract from the NIH's Rapid Acceleration of Diagnostics (RADx) initiative will enable the David Geffen School of Medicine at UCLA to expand its capacity to process COVID-19 tests.

A Rice University bioengineer and her Brown School of Engineering team were awarded an NIH grant to create gene activity sensors and activators that hold unmatched potential for the treatment of infectious diseases, diabetes, genetic disorders, and cancer. Source: AZO Life Sciences

NIBIB-funded research drives progress in the diagnosis, treatment, and monitoring of middle ear infections.

In a study that compares rapid antigen and laboratory PCR approaches for COVID-19 serial screening, researchers affiliated with the NIH RADx initiative reported results from 43 people infected with the virus.

In a new study, researchers have designed a miniaturized 3D-printed device to inactivate Pseudomonas aeruginosa, a common bacterium that causes the infection.

This study investigates how the nucleocapsid protein, or N protein, of the SARS-CoV-2 virus packages the viral genome.